TCF7L2 and type 2 diabetes mellitus: We have shown that TCF7L2 polymorphisms (rs12255372 and rs7903146) that have been consistently associated with type 2 diabetes are not significantly (P > 0.05) associated with any of the inflammatory markers in analyses before treatment with fenofibrate.